Implications of Relapse and Hospitalization Rates with Rituximab Use in NMOSD Management
December 2nd 2024A panelist discusses how comparing hospitalization rates, relapse risks, and safety considerations between rituximab and other NMOSD therapies, such as complement inhibitors, can provide valuable insights to guide treatment decisions, manage healthcare costs, and optimize patient quality of life.
Shared Decision-making for Selection of FDA-approved Therapies for NMOSD
November 25th 2024A panelist discusses how when treating NMOSD, neurologists should consider the patient's clinical characteristics, safety profiles, administration requirements, and cost-effectiveness when selecting between FDA-approved therapies such as eculizumab, inebilizumab, satralizumab, ravulizumab, and rituximab. Shared decision-making is crucial, involving close collaboration between the healthcare team and the patient to develop a personalized treatment plan that considers the patient's overall well-being.
Current Treatment Landscape of AQP4-IgG+ NMOSD and Considerations on Relapse Rates
November 18th 2024Michael Levy, MD, PhD, discusses how Aquaporin-4 IgG-seropositive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD) is a rare autoimmune condition affecting the central nervous system. Anti-CD20 therapies, particularly rituximab, have led to increased relapse rates.
Treatments With Higher Efficacy and Relapses in NMOSD
August 28th 2024This discussion examines how disability accumulation may be influenced by the use of less efficacious treatments, compares the efficacy of novel and traditional NMOSD agents in clinical practice, and reviews relapse rates associated with FDA-approved treatments versus off-label and older therapies.
Efficacy of Switching From to Inebilizumab in Rituximab in NMOSD: Michael Levy, MD, PhD
Published: May 16th 2024 | Updated: May 20th 2024The associate professor of neurology at Harvard Medical School talked about findings from a recent case series of patients with NMOSD initially on rituximab who then switched to inebilizumab. [WATCH TIME: 4 minutes]
Role of HCPs in Engaging Diverse NMOSD Patient Populations in Clinical Trials
October 28th 2022Mitzi Williams, MD; Mirla Avila, MD; Michael Levy, MD, PhD; and Michael Yeaman, PhD, explore how health care professionals can better engage diverse racial and ethnic groups with NMOSD to improve care and enroll in clinical trials.
Clinical Presentation of NMOSD and Overcoming Barriers to Access to Care
September 16th 2022Mirla Avila, MD; Michael Levy, MD, PhD; and Mitzi Williams, MD, share the clinical presentation and progression of NMOSD among various racial and ethnic groups and highlight the effects of socioeconomic disparities and personal barriers on access to proper care.